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Introduction
Millions of individuals are chronically exposed 
to inorganic arsenic via contaminated water 
sources and through diet (National Research 
Council 2014; Navas-Acien and Nachman 
2013). In the United States, an estimated 
17 million people have been exposed to 
drinking water sources containing arsenic 
levels exceeding the maximum contami-
nant limit of 10 μg/L [U.S. Environmental 
Protection Agency (EPA) 2000]. Common 
dietary staples, such as rice and poultry, have 
been found to contain elevated levels of 
arsenic that also contribute to an individual’s 
overall exposure (Cottingham et al. 2013; 
Davis et al. 2012; Gilbert-Diamond et al. 
2011; Nachman et al. 2013; Navas-Acien 
and Nachman 2013). Arsenic exposure has 
been associated with adverse health effects, 
including cancer, diabetes, and cardio vascular 
disease (National Research Council 2014).
Cardiovascular disease is the leading cause 
of morbidity and mortality worldwide (World 
Health Organization 2008), and associa-
tions between arsenic and the risk of cardio-
vascular events have been well documented 
in highly exposed populations (Chen et al. 
2011; Moon et al. 2012, 2013; States et al. 
2009). Recent prospective work in the United 
States observed a relation between low-level 
arsenic exposure and risk of cardio vascular 
disease (Moon et al. 2012, 2013). Indeed, a 
growing body of evidence suggests that arsenic 
may increase risks of some risk factors for 
cardio vascular diseases, including high blood 
pressure (BP), athero sclerosis, and endothe-
lial dysfunction (Chen et al. 2007a, 2007b, 
2013; Hsieh et al. 2011; Wang et al. 2007; 
Wu et al. 2012). However, available evidence 
on cardio vascular disease risk factors is based 
on cross-sectional studies, and prospective 
studies that characterize the magnitudes of 
longitudinal changes in risk factors related 
to arsenic exposure are lacking. Moreover, 
certain populations, such as pregnant women, 
may be especially susceptible to these adverse 
effects, but little is known about the cardio-
vascular effects of arsenic exposure during this 
time period.
Pregnancy profoundly alters both maternal 
anatomy and physiology to support fetal 
development (Cunningham et al. 2010). 
Pregnancy-induced hemodynamic adapta-
tions and hormonal changes lead to normal 
fluctuations in gestational BP (Cunningham 
et al. 2010). However, these changes can act as 
cardio vascular and metabolic stressors (Yoder 
et al. 2009), creating a “susceptible window” 
of risk for development of hypertension from 
putative triggers, including environmental 
exposures such as lead and air pollutants 
(Jedrychowski et al. 2012; Lee et al. 2012; van 
den Hooven et al. 2011; Yazbeck et al. 2009). 
Further, high BP during pregnancy can signal 
a greater risk of later-life maternal cardio-
vascular disease (Henriques et al. 2014; Irgens 
et al. 2001; Magnussen et al. 2009; Nisell 
et al. 1995; Skjaerven et al. 2012; Wilson et al. 
2003) and also enhances risk of adverse birth 
outcomes such as premature labor, placental 
abruption, and restricted placental blood 
flow to the fetus, which is related to low birth 
weight (Allen et al. 2004; Roberts et al. 2005).
In New Hampshire, about 40% of 
households rely on unregulated private water 
systems, of which 10–15% contain arsenic 
levels exceeding the maximum contaminant 
level (Karagas et al. 2002). As part of the 
New Hampshire Birth Cohort Study, we 
sought to investigate whether higher maternal 
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Background: Inorganic arsenic exposure has been related to the risk of increased blood pressure 
based largely on cross-sectional studies conducted in highly exposed populations. Pregnancy is 
a period of particular vulnerability to environmental insults. However, little is known about the 
cardiovascular impacts of arsenic exposure during pregnancy.
oBjectives: We evaluated the association between prenatal arsenic exposure and maternal blood 
pressure over the course of pregnancy in a U.S. population.
Methods: The New Hampshire Birth Cohort Study is an ongoing prospective cohort study in 
which > 10% of participant household wells exceed the arsenic maximum contaminant level of 
10 μg/L established by the U.S. EPA. Total urinary arsenic measured at 24–28 weeks gestation 
was measured and used as a biomarker of exposure during pregnancy in 514 pregnant women, 
18–45 years of age, who used a private well in their household. Outcomes were repeated blood 
pressure measurements (systolic, diastolic, and pulse pressure) recorded during pregnancy.
results: Using linear mixed effects models, we estimated that, on average, each 5-μg/L increase 
in urinary arsenic was associated with a 0.15-mmHg (95% CI: 0.02, 0.29; p = 0.022) increase in 
systolic blood pressure per month and a 0.14-mmHg (95% CI: 0.02, 0.25; p = 0.021) increase in 
pulse pressure per month over the course of pregnancy.
conclusions: In our U.S. cohort of pregnant women, arsenic exposure was associated with greater 
increases in blood pressure over the course of pregnancy. These findings may have important 
implications because even modest increases in blood pressure impact cardiovascular disease risk.
citation: Farzan SF, Chen Y, Wu F, Jiang J, Liu M, Baker E, Korrick SA, Karagas MR. 2015. 
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arsenic exposure during pregnancy is related 
to increases in maternal BP, an early cardio-
vascular disease risk factor and a complicating 
factor in pregnancy.
Methods
The New Hampshire Birth Cohort. In January 
2009, we began recruiting 18- to 45-year-
old pregnant women receiving prenatal 
care at study clinics, as previously described 
(Gilbert-Diamond et al. 2011). Women 
were enrolled at 24–28 weeks gestation if 
they reported using water from a private well 
at their residence since their last menstrual 
period and were not planning to move prior 
to delivery. Only singleton births are included 
in the study. All protocols were approved by 
the Dartmouth College Institutional Review 
Board. All participants provided written, 
informed consent upon enrollment.
Participants completed a detailed medical 
history and lifestyle questionnaire upon 
enrollment and a follow-up questionnaire 
at 2 weeks postpartum to provide updated 
information about changes in key exposures 
and prenatal complications. After delivery, 
participants’ medical records were reviewed 
to abstract pre- and post-delivery health 
information, including all clinically measured 
maternal BP levels, diagnoses of gestational 
diabetes, hyper tension, preeclampsia and 
eclampsia. Other clinical information was 
recorded to verify self-reported medical and 
reproductive history. Maternal systolic (SBP) 
and diastolic (DBP) BP was measured in 
the study clinics, using either automated or 
mercury sphygmomanometers, throughout 
pregnancy and was generally recorded at each 
prenatal visit. 
Arsenic exposure assessment. Women 
provided a spot urine sample upon enroll-
ment, which was collected and stored as 
previously described (Farzan et al. 2013; 
Gilbert-Diamond et al. 2011). Urine samples 
were analyzed for levels of arsenite (iAsIII), 
arsenate (iAsV), monomethyl arsonic acid 
(MMA), dimethyl arsinic acid (DMA), and 
arseno betaine by high-performance liquid 
chromatography (HPLC) inductively coupled 
plasma mass spectrometry (ICP-MS) at the 
University of Arizona Hazard Identification 
Core (Larsen et al. 1993; Le et al. 2000; Wei 
et al. 2001). Samples that registered below 
the detection limit (ranging from 0.10 
to 0.15 μg/L for individual species; 0.6%, 
16.5%, and 37.0% of the study population 
were below the detection limit for DMA, 
MMA, and iAs, respectively) were assigned a 
value equal to the detection limit divided by 
the square root of 2. Urinary creatinine levels 
(milligrams per deciliter) were determined 
using Cayman’s creatinine assay kit, according 
to the manufacturer’s instructions. Our 
primary exposure measure was total urinary 
arsenic at 24–28 weeks gestation, calculated 
by summing inorganic (iAs = iAsIII + iAsV) 
and organic (DMA, MMA) metabolites 
(Farzan et al. 2013; Gilbert-Diamond et al. 
2011). Arsenobetaine, an unmetabolized form 
of arsenic found in seafood, was excluded 
because it is considered nontoxic (Tseng 
2009). As secondary exposure measures, 
we examined the absolute values of urinary 
metabolites (MMA, DMA, and iAs). We also 
constructed primary (PMI) and secondary 
methylation indices (SMI) from ratios of 
MMA to iAs and DMA to MMA in urine, 
respectively, because these are considered 
indicators of methylation capacity that may 
impact individual variability in health effects 
of arsenic exposure (Chen et al. 2013). Upon 
enrollment, participants also were given 
instructions and prepaid mailing materials 
to collect samples of their home tap water 
and return the samples to the study office; 
these samples were analyzed by ICP-MS at 
the Dartmouth Trace Element Analysis Core, 
as previously described (Gilbert-Diamond 
et al. 2011). Maternal toenail samples were 
collected at 2 weeks postpartum, washed five 
times by sonication in a solution of Triton 
X-100 and acetone, followed by deionized 
water, and then dried before low-pressure 
microwave digestion. Samples were analyzed 
for trace elements previously related to BP 
(i.e., selenium, cadmium, iron, mercury, 
and lead) (Houston 2007; Kennedy et al. 
2012; Wells et al. 2012) using ICP-MS as 
previously described for arsenic (Davis 
et al. 2014).
Statistical analysis. We confined our 
analysis to women without a history of hyper-
tension prior to pregnancy with at least two 
pregnancy BP measurements. Our outcomes 
of interest were temporal changes in SBP, 
DBP, and pulse pressure (PP; SBP minus 
DBP) during pregnancy, which were analyzed 
as continuous variables with repeated 
measurements. For each measurement, we 
calculated the trimester and gestational week, 
based on the participant’s last menstrual 
period. We restricted our analysis to measure-
ments taken after 13 weeks gestation due to 
the low number of measurements recorded 
before this time. Measurements outside 
of a reasonable range (i.e., SBP: < 40 or 
> 250 mmHg, DBP: < 35 or > 180 mmHg) 
(Lee et al. 2012) were likely incorrectly 
recorded at time of measurement or incor-
rectly extracted from the medical record. All 
values that were excluded were well outside of 
the physiologically plausible range and were 
coded as missing (< 1% of measurements, 
n = 9). All other values recorded for these 
women were within a physio logically reason-
able range. There were few cases of diagnosed 
pregnancy-induced hypertension (n = 15) or 
preeclampsia (n = 9) in our study population; 
thus, it was not possible to analyze these 
outcomes separately.
We  f i t t e d  m i xe d - e f f e c t  m o d e l s 
(Demidenko 2004) of the repeated BP 
measurements to examine whether maternal 
urinary total arsenic or arsenic metabolite 
concentrations influenced SBP, DBP, and PP 
over the course of pregnancy, as follows:
BPij = [β0 + β1(TIME)ij + β2As0j  
 + β12As0j(TIME)ij + αTZ0j]  
 + [μ0j + μ1j(TIME)ij] + rij, [1]
where BP ij represents BP at time i for 
subject j, As0j is urinary arsenic (total, DMA, 
MMA, or iAs) at baseline (time 0 represents 
baseline; i.e., the gestational month of each 
woman’s first BP measurement after 13 weeks 
gestation) for subject j; TIME is gestational 
month of BP measurement; β1 is the coef-
ficient for the association between TIME and 
BP when arsenic is held constant; β2 is the 
difference in BP for every unit increase in 
arsenic at baseline; β12 is the difference in 
monthly BP change over pregnancy per unit 
increase in arsenic (i.e., the estimated effect 
of arsenic levels on monthly BP change); αT 
is a row vector of regression coefficients for 
covariates at baseline (T denotes vector trans-
pose); Z0j is a vector of covariates at baseline. 
The random intercept μ0j and slope μ1j esti-
mated the within-subject correlation among 
repeated measurements and between-subject 
hetero geneity, and rij is the error that cannot 
be accounted for by other covariates and 
random effects. The terms in the first and 
second brackets are the fixed and random 
parts of the model, respectively. We assessed 
non linear trends in the data using the same 
modeling strategy described above, including 
model terms to examine the interaction 
between TIME and categories of arsenic 
exposure variables (e.g., dummy variables for 
arsenic tertiles), as well as linearity of the time 
effect by including an additional interaction 
term between As0j and TIME2. Neither test 
provided evidence of a nonlinear association 
(p > 0.05). For ease of interpretation, 5 μg/L 
(~ 1 SD) was used as the unit to report 
effect estimates for total urinary arsenic and 
metabo lite levels.
Our models were adjusted for available 
covariates that could potentially influence BP 
based on a priori considera tions, including age 
at enrollment, prepregnancy body mass index 
(BMI), smoking during pregnancy, marital 
status, educational attainment, gestational 
diabetes, parity, and number of BP measure-
ments. As described above, we included the 
month of gestation during which each BP 
measurement was obtained in our models. 
We considered pregnancy BP measurements 
after 13 weeks gestation (our baseline) in 
our models because few subjects received 
Arsenic exposure and gestational blood pressure
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BP measurements prior to that time point. 
Urinary arsenic concentrations were used 
as a measure of gestational arsenic exposure 
because urine samples earlier in pregnancy 
were not available and prior studies suggest 
that total arsenic concentrations remain rela-
tively stable (Ahmed et al. 2011; Gamble 
et al. 2006). Because there is some debate as 
to whether creatinine adjustment is appro-
priate for urinary arsenic measures, we also 
tested models with and without urinary 
creatinine adjustment. We also tested inclu-
sion of arseno betaine levels as a covariate in 
our models. We found that neither creati-
nine nor arseno betaine adjustment altered 
our estimates: Results were unchanged with 
or without creatinine adjustment {i.e., SBP 
β12 0.15 [95% confidence interval (CI): 
0.02, 0.29] with creatinine adjustment}, as 
well as with or without arsenobetaine adjust-
ment [i.e., SBP β12 0.15 (95% CI: 0.02, 0.29) 
with arsenobetaine adjustment] (data not 
shown). For individuals with missing covariate 
data (Table 1), we used multiple imputation 
to estimate missing covariate values (Little 
and Rubin 2002). We examined the missing 
data patterns; in our models we assumed 
that the data were missing at random with a 
monotone structure. We used the regression 
method within the SAS PROC MI proce-
dure to generate five imputed data sets, then 
used the PROC MIANALYZE procedure to 
generate inferences for both the mixed and 
linear regression models. We also performed 
sensitivity analyses by excluding participants 
who smoked during pregnancy or those who 
developed gestational diabetes to evaluate the 
impact on our results, because BP may be 
altered in these groups (Bakker et al. 2010; 
Bryson et al. 2003; Carpenter 2007; Matkin 
et al. 1999). We also assessed other exposures 
from toenail levels as potential confounders. 
Toenail elements that have been associated 
with BP in the literature, such as selenium, 
cadmium, iron, mercury, and lead (Houston 
2007; Kennedy et al. 2012; Wells et al. 2012), 
all had little to very weak correlations with 
toenail arsenic (r < 0.20) (data not shown) and 
thus were not adjusted for in our analysis.
We conducted analyses stratified by PMI 
or SMI, using the median values (0.89 and 
9.66, respectively) as cut points, to assess 
whether the association between urinary 
arsenic and BP changes over time differed by 
these arsenic methylation indices. We also 
performed analyses stratified by age (below 
or at/above a median of 30.9 years), history 
of prior pregnancy (nulliparous or parous), 
prepregnancy BMI (< 25 or ≥ 25 kg/m2).
Because BP increases over the latter part 
of pregnancy (Cunningham et al. 2010; 
Miller et al. 2007; Thompson et al. 2007), 
we further examined whether women with 
higher urinary arsenic had higher BP at 
the end of pregnancy, using linear regres-
sion models with the outcome, respectively 
defined as the average of the last three BP 
measurements (SBP, DBP, PP), adjusting for 
the same covariate variables. The equation 
generated from the multi variable linear 
regression model was also used to graphically 
represent the relationship between maternal 
urinary arsenic and SBP at the end of 
pregnancy, when all covariates are set equal to 
the median values (Figure 1). In all analyses, 
p-values < 0.05 were considered significant. 
All analyses were performed using SAS 9.3 
(SAS Institute Inc.).
Results
As of 30 October 2013, 620 participants had 
available urinary arsenic measurements and, 
of these, 590 had available medical record 
review data. As an a priori selection require-
ment, we required women to have at least two 
BP measurements taken during pregnancy; 
however, all 527 women in this sample had 
a minimum of four measurements. An addi-
tional 13 women with a history of hyper-
tension were excluded, resulting in a final 
sample size of 514. This subset was similar 
to the overall cohort (n = 620) with respect 
to demographic and lifestyle variables (data 
Table 1. Selected characteristics of women enrolled in the New Hampshire Birth Cohort Study (n = 514), categorized by tertiles of total urinary arsenic (U‑As) 
measurements during pregnancy. 
Variable
Overall U-As  
(0.35–288.5 μg/L)  
n = 514
Tertile 1 U-As  
(0.35–2.54 μg/L) 
n = 171
Tertile 2 U-As 
(2.54–5.34 μg/L) 
n = 171
Tertile 3 U-As 
(5.34–288.5 μg/L) 
n = 172
Age at enrollment (years) 31.1 ± 4.9 (18.5–44.6) 30.7 ± 4.9 (19.3–44.4) 31.5 ± 4.9 (18.5–44.6) 31.2 ± 4.9 (19.1–43.4)
Level of education
< 11th grade 4 (0.9) 0 (0) 2 (1.4) 2 (1.4)
High school graduate 43 (9.9) 21 (14.9) 13 (9.0) 9 (6.3)
Junior college, some college, technical school 94 (21.6) 28 (18.8) 30 (20.7) 36 (25.4)
College graduate 173 (39.7) 57 (38.3) 60 (41.8) 56 (39.4)
Postgraduate schooling 122 (28.0) 43 (28.9) 40 (27.6) 39 (27.5)
Missing 78 22 26 30
Relationship status
Married 377 (86.1) 128 (85.3) 130 (89.0) 119 (83.8)
Single 48 (11.0) 19 (12.7) 12 (8.2) 17 (12.0)
Divorced, widowed 13 (3.0) 3 (2.0) 4 (2.7) 6 (4.2)
Missing 76 21 25 30
Prepregnancy BMI (kg/m2) 25.1 ± 5.1 (17.6–48.3) 24.5 ± 4.5 (18.0–42.5) 25.2 ± 5.0 (17.6–45.7) 25.7 ± 5.8 (17.6–48.3)
Missing 77 21 25 31
Parity
0 197 (38.5) 70 (41.4) 67 (39.2) 60 (34.9)
1 200 (39.1) 65 (38.5) 64 (37.4) 71 (41.3)
≥ 2 115 (22.5) 34 (20.1) 40 (23.4) 41 (23.8)
Missing 2 2 0 0
Developed gestational hypertension 8 (1.6) 4 (2.3) 1 (0.6) 3 (1.7)
Developed gestational diabetes 36 (7.0) 11 (6.4) 15 (8.8) 10 (5.8)
Smoked during pregnancy 26 (5.8) 10 (2.9) 4 (2.3) 12 (7.0)
Missing 66 18 22 26
Well water arsenic
Mean (μg/L) 4.3 ± 11.0 (0.0–147.7) 2.2 ± 5.9 (0.0–58.0) 3.1 ± 8.2 (0.0–67.5) 7.7 ± 15.9 (0.0–147.7)*
> 10 μg/L MCL 58 (12.5) 10 (5.8) 11 (6.4) 37 (21.5)
Missing 51 15 15 21
MCL, maximum contaminant limit. Data are n (%) or mean ± SD (range). Frequencies and means were compared by chi‑square or one‑way analysis of variance (ANOVA), respectively. 
*p < 0.001 compared with tertile 1. 
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not shown). Women in this sample had 
urinary arsenic concentrations ranging from 
0.35 to 288.5 μg/L, which was very similar 
to the range observed in the overall cohort 
(0.08–288.5 μg/L). Of the subset of partici-
pants included in these analyses, 472 had 
provided water samples, 463 of which had 
been analyzed at the time of this study 
and had a mean arsenic level of 4.3 μg/L 
(range, 0–147.7 μg/L). Nearly 1 in every 
8 households (58 of 463 available samples; 
12.5%) tested in this subsample had water 
arsenic levels > 10 μg/L. In our study group, 
well water arsenic levels were significantly 
correlated with urinary arsenic measure-
ments (r = 0.40, p < 0.001). No differences 
in the descriptive variables were observed 
across urinary arsenic tertiles by chi-square 
or one-way analysis of variance (ANOVA) 
tests, except for water arsenic levels, in which 
the third tertile was higher than the first 
tertile (Table 1).
The 514 women in this subsample of 
the cohort contributed a total of 6,675 SBP 
and 6,671 DBP measurements (5,773 SBP 
and 5,769 DBP after gestational week 13). 
On average, 13 (range, 4–24) BP measure-
ments were recorded per participant during 
pregnancy, with more than half occurring 
in the last trimester. Both SBP and DBP 
increased during pregnancy (Figure 1; 
see also Supplemental Material, Table S1), 
with the highest averages for both SBP and 
DBP occurring in the third trimester (SBP 
trimester mean ± SD: first, 112.9 ± 9.8; 
second, 112.5 ± 8.2; third, 115.3 ± 8.4; 
DBP trimester mean ± SD: first, 68.4 ± 7.7; 
second, 67.0 ± 6.0; third, 69.4 ± 6.2). PP 
also appeared to increase over the course 
of pregnancy, with somewhat more vari-
ability (Figure 1; see also Supplemental 
Material, Table S1).
We observed no association between 
urinary arsenic and differences in DBP change 
over pregnancy. Arsenic exposure was related 
to greater monthly increases in SBP and PP 
change over the course of pregnancy (Table 2). 
Based on our model, each 5-μg/L increase in 
urinary arsenic was associated with a 0.15-
mmHg greater monthly increase in SBP (95% 
CI: 0.02, 0.29; p = 0.022) and a 0.14-mmHg 
greater monthly increase in PP (95% CI: 
0.02, 0.25; p = 0.021) over the course of 
pregnancy (Table 2). In sensitivity analyses, 
excluding smokers or individuals with gesta-
tional diabetes did not appreciably alter 
any of these findings (data not shown). The 
metabolites MMA, DMA, and iAs were all 
positively associated with greater increases in 
PP over the course of pregnancy [MMA β12, 
1.54 (95% CI: 0.16, 2.92); DMA β12, 0.15 
(95% CI: 0.02, 0.29); iAs β12, 1.18 (95% CI: 
–0.01, 2.38)] (Table 2). Higher levels of DMA 
were also associated with greater increases in 
SBP [β12, 0.18 (95% CI: 0.02, 0.33)] over the 
course of pregnancy.
Women with higher PMI had greater 
average increases in both SBP and PP over 
the course of pregnancy compared with 
those with lower PMI, although the differ-
ences from women with lower PMI were 
not significant [SBP β12, 0.23 (95% CI: 
0.07,  0.39) vs .  β12,  0.06 (95% CI: 
–0.17, 0.29; p-interaction = 0.21); PP β12, 
Figure 1. Blood pressure measurements over pregnancy by gestational week. For each 2‑week period, 
all systolic blood pressure (A), diastolic blood pressure (B), or pulse pressure (C) measurements during 
that time were averaged individually for each woman and then averaged across all women and plotted. 
Error bars represent the 95% CIs. Measurements prior to 6 weeks of gestation were excluded due to few 
available measurements. 
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0.18 (95% CI: 0.03, 0.34) vs. β12, 0.10 
(95% CI: –0.10, 0.29; p-interaction = 0.47)] 
(Table 3). Similarly, those with higher SMI 
appeared to have greater increases in SBP 
[high SMI β12, 0.25 (95% CI: 0.07, 0.42) 
vs. low SMI β12, 0.05 (95% CI: –0.15, 0.26; 
p-interaction = 0.17)] over the course of 
pregnancy, although the test for interaction 
was not significant. No effect modification by 
SMI was observed for PP (high SMI β12, 0.16 
(95% CI: 0.01, 0.31) vs. low SMI β12, 0.12 
(95% CI: –0.06, 0.31; p-interaction = 0.74)]. 
In analyses stratified by potential effect 
modifiers, including pre pregnancy BMI, age, 
and parity, we observe no statistically signifi-
cant associations between total urinary arsenic 
and longitudinal changes in BP (data not 
shown). We also examined whether individuals 
with missing data affected the outcomes and 
found that, when individuals with missing 
covariate information (n = 78) were excluded, 
the estimates were nearly unchanged [i.e., 
SBP β12, 0.15 (95% CI: 0.02, 0.28)] (data 
not shown).
When we conducted simple linear 
regression models, based on the average of 
the last three BP measurements, each 5-μg/L 
increase in urinary arsenic was associated 
with a 0.78-mmHg (95% CI: 0.05, 1.51; 
p = 0.035) higher SBP. Again, total urinary 
arsenic was unrelated to DBP [β = 0.34 
(95% CI: –0.20, 0.89; p = 0.22)]. Likewise, as 
in the longitudinal analysis, PP was positively 
associated with urinary arsenic, but with 
wide confidence intervals [β = 0.44 (95% CI: 
–0.10, 0.97; p = 0.11)]. Graphical representa-
tion of the linear regression model depicts an 
increase in the average of the last three SBP 
measurements in relation to urinary arsenic 
level (see Supplemental Material, Figure S1).
Discussion
To our knowledge, our study is the first 
prospective study to examine the associa-
tion between arsenic and BP in the context 
of pregnancy and among the few studies on 
the cardio vascular effects of arsenic exposure 
in the United States. Because pregnancy is a 
vulnerable window of susceptibility to adverse 
BP changes, by focusing on a cohort of 
pregnant women we found that higher levels 
of urinary arsenic during pregnancy prospec-
tively related to greater increases in SBP and 
PP over the course of pregnancy.
Arsenic has been associated with a range 
of cardio vascular outcomes in populations 
with appreciable levels of chronic exposure, 
such as in Bangladesh and Taiwan, including 
increased risks of fatal and nonfatal cardio-
vascular disease, as well as inter mediary 
factors, such as increased carotid intima-
media thickness and metabolic syndrome 
(Chen CJ et al. 1995; Chen Y et al. 2007a, 
2011, 2013; Kwok et al. 2007; Wang et al. 
2007; Wu et al. 1989). Arsenic has been 
associated with hyper tension in a number of 
cross-sectional studies, from which a meta-
analysis derived a pooled odds ratio for hyper-
tension of 1.27 (95% CI: 1.09, 1.47) for high 
versus low arsenic exposure (Abhyankar et al. 
2012). Although potential causal mechanisms 
for the association between arsenic and BP 
increase during pregnancy have not yet been 
explored, many of the mechanisms hypoth-
esized to explain associations with other 
cardio vascular outcomes could be involved. 
Arsenic exposure has been related to increased 
plasma markers of inflammation and endo-
thelial damage (Burgess et al. 2013; Chen 
et al. 2007b; Wu et al. 2012), suggesting 
that arsenic may act in part by promoting 
endothelial dysfunction, pathologic vascular 
remodeling, and atherosclerosis. Thus, while 
speculative, arsenic exposure could impact the 
pregnancy-related hemo dynamic adaptations 
that increase blood volume and maintain 
placental perfusion, which is critical to fetal 
nutrient and oxygen supply.
BP normally increases toward the latter 
part of pregnancy, with increases in SBP 
generally tending to be somewhat more 
pronounced than those in DBP (Cunningham 
et al. 2010; Miller et al. 2007; Thompson 
et al. 2007). A prospective study of longitu-
dinal BP during pregnancy reported average 
increases of about 3.7 mmHg and 2.2 mmHg 
between the first and third trimesters for SBP 
and DBP, respectively (Miller et al. 2007). 
Abnormal increases pose a serious risk of 
complications during pregnancy such as 
preterm birth, low birth weight, fetal growth 
restriction, and perinatal mortality (Ray et al. 
2001; Xiong and Fraser 2004; Zhang et al. 
2007) and the deleterious effects of gestational 
hypertension (defined as new onset of SBP 
Table 2. Relation between pregnancy urinary arsenic and changes in blood pressure (mmHg) per month over pregnancy among 514 women in the New 
Hampshire Birth Cohort Study.
As exposure measure 
(per 5 μg/L)
No. of BP 
measurements
SBP DBP PP
β12 (95% CI)a p-Valueb β12 (95% CI)a p-Valueb β12 (95% CI)a p-Valueb
Total As 5,032 0.15 (0.02, 0.29) 0.022 0.02 (–0.08, 0.12) 0.73 0.14 (0.02, 0.25) 0.021
MMA 5,016 1.28 (–0.27, 2.83) 0.11 –0.25 (–1.45, 0.96) 0.69 1.54 (0.16, 2.92) 0.028
DMA 5,032 0.18 (0.02, 0.33) 0.022 0.03 (–0.09, 0.14) 0.67 0.15 (0.02, 0.29) 0.027
iAs 5,031 1.11 (–0.23, 2.44) 0.10 –0.01 (–1.04, 1.03) 0.98 1.18 (–0.01, 2.38) 0.052
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure. 
aCoefficient in relation to interaction between a 5‑μg/L increase in total urinary arsenic, MMA, DMA, or iAs and each month of gestation; adjusted for age at enrollment, prepregnancy 
BMI, educational level, marital status, maternal smoking, parity, gestational diabetes, and number of blood pressure measurements per participant. bp‑Values for β12 effect estimates.
Table 3. Relation between pregnancy total urinary arsenic and changes in blood pressure (mmHg) over pregnancy among 514 women in the New Hampshire 
Birth Cohort Study, stratified by methylation indices.
Methylation index
No. of BP 
measurements
SBP DBP PP
β12 (95% CI)a p-Valueb β12 (95% CI)a p-Valueb β12 (95% CI)a p-Valueb
PMI 
Low 2,535 0.06 (–0.17, 0.29) 0.60 –0.02 (–0.19, 0.14) 0.76 0.10 (–0.10, 0.29) 0.33
High 2,475 0.23 (0.07, 0.39) 0.004 0.05 (–0.09, 0.19) 0.51 0.18 (0.03, 0.34) 0.021
p for interactionc 0.21 0.52 0.47
SMI 
Low 2,464 0.05 (–0.15, 0.26) 0.61 –0.06 (–0.22, 0.10) 0.47 0.12 (–0.06, 0.31) 0.19
High 2,546 0.25 (0.07, 0.42) 0.005 0.09 (–0.05, 0.22) 0.22 0.16 (0.01, 0.31) 0.040
p for interactionc 0.17 0.17 0.74
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; PMI, primary methylation index (MMA/iAs); PP, pulse pressure; SBP, systolic blood pressure; SMI, secondary 
methylation index (DMA/MMA). 
aCoefficient in relation to interaction between a 5‑μg/L increase in total urinary arsenic and each month of gestation; adjusted for age at enrollment, prepregnancy BMI, educational 
level, marital status, maternal smoking, parity, gestational diabetes, and number of blood pressure measurements per participant. bp‑Values for β12 effect estimates. cp for interaction, 
based on two‑tailed tests of significance.
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> 140 mmHg and/or DBP > 90 mmHg in 
second trimester) are well known. However, 
elevations in BP that do not exceed the 
upper threshold of the normal range (SBP 
< 140 mmHg and DBP < 90 mmHg) may 
also pose risks to the mother and child. For 
nonpregnant adults, the risk of cardio vascular 
disease increases linearly as BP increases, even 
within the normo tensive range (Vasan et al. 
2001; Williams et al. 2008). A few studies 
have examined BP as a continuous measure 
and found that higher BP, even within the 
normotensive range, also may impact birth 
weight and intra uterine growth restriction 
(Churchill et al. 1997; Fukushima et al. 
2012). It is possible that elevated BP, albeit 
within the clinically normal range, alters 
uterine and placental perfusion, and impacts 
fetal growth. Our results suggest that there 
were greater increases in SBP and PP over 
pregnancy associated with higher arsenic 
exposure, leading to greater relative differences 
at the end of pregnancy. However, the clinical 
significance of greater increases in BP remains 
to be explored, and more studies utilizing 
continuous BP outcome measures are needed 
to examine the relation between BP elevations 
within the normal range and health risks.
Pregnancy itself is a cardio vascular stressor. 
In a rodent study, normal, healthy pregnan-
cies were found to induce long-term altera-
tions in cardio vascular and renal function 
that were absent in nonparous females (Gallo 
et al. 2012). Pregnancy-induced hyper tension 
has been associated with increased later life 
risk of chronic hypertension, endothelial 
dysfunction, and kidney disease (Henriques 
et al. 2014; Nisell et al. 1995; Vikse et al. 
2008; Wang et al. 2013; Wilson et al. 2003). 
According to a recent study, women with a 
history of a hypertensive pregnancy had 
nearly 60% greater odds of peripheral artery 
disease compared with those with normo-
tensive histories, even decades after pregnancy 
(Weissgerber et al. 2013). Additional longitu-
dinal studies are needed to determine whether 
BP changes during pregnancy, such as those 
observed in relation to arsenic exposure in our 
cohort, lead to long-term health consequences 
for mother and child.
In our study, we found that each 5 μg/L 
urinary arsenic was associated with an average 
SBP increase of 0.15 mmHg per month and a 
0.78-mmHg (95% CI: 0.05, 1.51; p = 0.035) 
higher SBP. Although we are unaware of any 
previous studies of arsenic and BP during 
pregnancy, recent studies have found that 
exposure to other environmental contami-
nants may affect BP during pregnancy with 
similar magnitudes of effects as observed in 
our study. Several studies have observed asso-
ciations between particulate air pollution and 
increased BP in pregnant women (Lee et al. 
2012; van den Hooven et al. 2011), including 
a prospective study of 431 pregnant women 
that found third-trimester SBP increased 
linearly with second-trimester exposure to air 
particulates (Jedrychowski et al. 2012). The 
Generation R Study found that a 10-μg/m3 
increase in PM10 exposure was associated with 
greater increases in SBP over the second and 
third trimesters: 1.11 (95% CI: 0.43, 1.79) 
and 2.11 (95% CI: 1.34, 2.89) mmHg, 
respectively (van den Hooven et al. 2011). 
A recent U.S. cohort study of air pollution 
on BP changes over the course of pregnancy 
found that interquartile increases in PM10 
(particulate matter ≤ 10 μm in aerodynamic 
diameter) and ozone exposure in the first 
trimester were associated with average SBP 
increases of 1.9 mmHg (95% CI: 0.84, 2.93) 
and 1.8 mmHg (95% CI: 1.05, 4.63), 
respectively, an association that was more 
pronounced in non smoking mothers (Lee 
et al. 2012). In addition, a cohort study of 
1,017 pregnant women in France found an 
association between mid pregnancy blood 
lead levels and increased risk of pregnancy-
induced hyper tension in the second and third 
trimesters (Yazbeck et al. 2009). Although 
studies of the impacts of environmental toxi-
cants on cardio vascular effects during preg-
nancy are increasing, more studies are needed 
to assess the vulnerable times of exposure, 
as well as the effects of toxicants known to 
increase cardio vascular disease in non pregnant 
adults, including arsenic.
Ingested inorganic arsenic is primarily 
metabolized via methylation, first to MMA, 
then to DMA. Arsenic metabolism varies 
greatly between individuals, and higher 
MMA proportions are indicative of ineffi-
cient methyla tion (Buchet et al. 1981; Vahter 
1999). MMA, thought to be a more toxic 
metabolite, has been linked to adverse health 
effects, including cardio vascular effects (Chen 
et al. 2013; Huang et al. 2009). Because 
previous work from more highly exposed indi-
viduals has indicated that higher PMI may 
be associated with greater health risks (Chen 
et al. 2013), one might expect to see stronger 
effects only in those with high PMI, which 
could indicate inefficient arsenic metabolism, 
as opposed to high SMI, which may indicate 
more efficient methyla tion and therefore 
arsenic excretion. However, we observed 
associations between urinary arsenic and BP 
both among those with higher PMI or higher 
SMI, although differences may have occurred 
by chance. In populations with lower overall 
levels of exposure, one might predict that the 
majority of ingested arsenic, once methylated 
to MMA, would be more easily methylated 
to DMA. This prediction is consistent with 
our observations, as well as with those in other 
U.S. populations, including recent results 
from the Strong Heart Study, which indicated 
that higher DMA proportions were linked to 
cardio vascular disease incidence and mortality, 
raising the possibility for a role of higher SMI 
in cardio vascular risk in populations with low 
arsenic exposure levels (Moon et al. 2013). 
A low SMI may be a susceptibility factor in 
more highly exposed populations, such as in 
Bangladesh. Further, the pregnancy-related 
health outcomes related to high SMI (i.e., 
high DMA levels) are less well understood. 
It is possible that women with altered 
arsenic metabolism may be more susceptible 
to arsenic’s cardio vascular effects and more 
likely to experience increases in BP during 
pregnancy. Interestingly, in late pregnancy, 
a greater proportion of arsenic is excreted 
as MMA (Concha et al. 1998; Hopenhayn 
et al. 2003), possibly representing a detoxifica-
tion mechanism. Although this pregnancy-
related alteration in metabolism is not well 
understood, it is possible that this mechanism 
may in part account for the observed asso-
ciation between increased BP in association 
with both PMI and SMI. Further study of the 
effect modification by arsenic metabolites is 
warranted, particularly at the lower levels of 
arsenic exposure found in U.S. populations.
Urinary arsenic is considered to be a 
reliable short-term measure of arsenic exposure 
that appears to remain relatively consistent in 
adults, even during pregnancy (Ahmed et al. 
2011; Gamble et al. 2006). In the present 
study, we collected urine samples over a 
narrow gestational time frame, during which 
concentrations were previously found not 
to vary (Gilbert-Diamond et al. 2011). To 
examine the trajectory of BP over pregnancy, 
we used measurements beginning at 13 weeks 
gestation; thus, some measurements were 
taken prior to urine sampling. However, prior 
studies suggest that total urinary arsenic levels 
remain relatively constant over pregnancy 
(Ahmed et al. 2011). However, our single 
exposure measurement may not be represen-
tative of typical exposure levels for all of the 
women in our study sample, and there may 
be variability in arsenic exposure levels that 
we were unable to account for in this study. 
Further, the study by Gamble et al. (2006) 
was performed in adults, and urinary arsenic 
stability may vary between non pregnant and 
pregnant adults. Although we did not collect 
multiple urine samples from participants, we 
collected maternal toenail samples prior to 
delivery, which approximately represent the 
previous 6–9 months of exposure. Among 
334 women in our study with both prenatal 
urinary and toenail arsenic measurements, 
toenail arsenic was positively correlated with 
urinary arsenic measurements (r = 0.33, 
p < 0.001; data not shown). Moreover, use 
of urine as an arsenic biomarker allows us 
to account for exposure from other sources, 
such as diet. Nearly 1 in 8 individuals 
(12.5%) in this sample had water arsenic 
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levels that exceeded the U.S. EPA maximum 
contaminant limit of 10 μg/L, which likely 
represents the primary source of arsenic 
exposure among these individuals. Further, 
work from our study area of New Hampshire 
has found that a variety of foods, including 
rice, can also significantly increase an indi-
vidual’s arsenic exposure (Cottingham et al. 
2013; Gilbert-Diamond et al. 2011).
Our study has some potential limitations. 
First, we used measurements of BP at 
prenatal care visits, obtained from medical 
records. These measurements reflect the 
types of measurements and patterns that are 
obtained in routine clinical settings; although 
standard medical procedures were used, 
differences in staff and instrumentation may 
have introduced random variability into our 
measurements. In addition, BP can fluctuate 
acutely in relation to anxiety, recent exertion, 
and caffeine consumption, contributing to 
measurement error. Although we were not 
able to account for these factors in our 
models, we would not expect instrumenta-
tion to be related to exposure status and error 
in the precision of measurement techniques 
that would likely bias our estimates toward 
the null. We also were unable to account for 
dietary factors (i.e., high sodium consump-
tion, nutrient levels) that have the potential 
to impact BP levels, and due to sample size, 
we may have been limited in our ability 
to examine the impact of effect modifiers, 
such as age or BMI. Our study population 
of mothers tended to be well-educated and 
primarily white, which may underrepresent 
different racial or socio economic groups that 
are at higher risk of gestational hypertension. 
Nonetheless, internal validity of the study 
is strengthened by the fact that we have 
multiple measurements for each woman over 
the course of pregnancy, detailed medical 
history, and socio demographic informa-
tion from our participants to include in 
our models. However, some women in our 
study were missing covariate information. 
We used multiple imputation methods to 
impute missing data, and we cannot rule out 
the possibility that data were not missing 
completely at random. Further, our choice of 
mixed models helps to account for random 
variability. Longitudinal data analysis provides 
a sensitive tool for charac terizing health 
outcomes that change gradually, such as BP, 
and repeated measures can be a powerful way 
to identify small changes that can have a large 
impact at the population level (Farrington 
1991). BP has a strong, continuous positive 
association with cardio vascular disease (Law 
et al. 2003; MacMahon et al. 1990; Sagie 
et al. 1993), and as SBP increases above 
115 mmHg, the risk of cardio vascular 
disease rises continuously (Vasan et al. 
2001; Williams et al. 2008). Therefore, the 
changes observed here have the potential to 
impact maternal cardio vascular risks (Law 
et al. 2003).
It is becoming increasingly evident that 
pregnant women and developing fetuses are 
particularly vulnerable to environmental 
insults. Inorganic arsenic consumed in both 
drinking water and diet may contribute 
to overall arsenic burden in U.S. pregnant 
women. Although the adverse cardio vascular 
effects of arsenic have been investigated in 
adults, to our knowledge, our study is among 
the first to examine these impacts during 
pregnancy. As cardio vascular morbidity and 
mortality rise worldwide, the potential risk 
of later-life cardio vascular diseases in mothers 
and children who are exposed to arsenic 
during pregnancy makes this a critical area of 
investigation.
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